{"id":"45501dcaa0e5","type":"article","url":"https://hartvaat.nl/2026/11/04/bijwerkingen-van-lipidverlagers-bij-familiaire-hypercholesterolemie-verschillen-/","title":"Bijwerkingen van lipidverlagers bij familiaire hypercholesterolemie verschillen per geslacht","title_en":"Sex-specific clinical and psychosocial characteristics among individuals with familial hypercholesterolemia reporting side-effects of lipid-lowering therapy","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Atherosclerosis","doi":"10.1016/j.atherosclerosis.2026.121950","source_url":"https://doi.org/10.1016/j.atherosclerosis.2026.121950","authors":["Amara Synøve Øgaard Uduma","Elise Sverre","John Munkhaugen","Kjetil Retterstøl","Kirsten B. Holven","Nils Tore Vethe"],"significance":5,"published":"2026-11-12","source_date":"2026-11-04","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/dutch-lipid-clinic-network-score/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"An observational study in patients with familial hypercholesterolemia (FH) identifies the clinical and psychosocial characteristics associated with self-reported side effects of lipid-lowering therapy. The analysis demonstrates that symptom reporting and contributing factors differ between men and women. For clinical practice, this underscores the importance of sex-specific assessment of therapy intolerance and psychosocial burden to optimize adherence in FH management.","created":"2026-11-05T02:38:07Z","updated":"2026-11-05T02:38:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Een observatiestudie onder patiënten met familiaire hypercholesterolemie (FH) brengt de klinische en psychosociale kenmerken in kaart die samenhangen met zelfgerapporteerde bijwerkingen van lipidverlagers. De analyse toont aan dat de verslaggeving van bijwerkingen en de onderliggende factoren verschillen tussen mannen en vrouwen. Voor de dagelijkse praktijk betekent dit dat geslachtsspecifieke vragen naar therapie-intolerantie en psychosociale belastbaarheid essentieel zijn om adherentie te waarborgen.","abstract_original":"Symptoms attributed to lipid-lowering therapy (LLT) may affect adherence. We explored sex-specific clinical and psychosocial characteristics associated with self-perceived side-effects of LLT in individuals with familial hypercholesterolemia (FH)."}